Claims for Patent: 9,962,333

Summary for Patent: 9,962,333

Title:	Timed release of substances to treat ocular disorders
Abstract:	A system is disclosed for simple, non-invasive, sustained delivery of ophthalmic substances to the interior of the eye, for the prevention and treatment of eye diseases and conditions. Liposomes and inverted micelles are disclosed as suitable vehicles, and timed release of the substances is effected. Delivery methods include coating of a lens or injection into the eye.
Inventor(s):	Gaillard; Elizabeth (Dekalb, IL), Dillon; James (Dekalb, IL), Friedrichs; Jason (Sycamore, IL), Xu; Tao (Lisle, IL), Hagen; Timothy J. (Lisle, IL), Karumanchi; Devi Kalyan (Dekalb, IL)
Assignee:	Board of Trustees of Northern Illinois University (DeKalb, IL)
Application Number:	14/907,745
Patent Claims:	1. A liposomal formulation for ocular drug delivery, the formulation defined as: (a) comprising liposomes with particle sizes selected from the group consisting of 100 to 200 nm hydrodynamic diameters; (b) exhibiting increased percent encapsulation of drugs into the liposomes compared to encapsulation using a standard, not modified, liposomal formulation; and (c) comprising a cocktail of at least three different liposomal formulations with hydrophobic anti-oxidants encapsulated within the lipid bilayers, wherein the hydrophobic antioxidants are selected from the group consisting of beta carotene and canthaxanthin, and comprising PC:PE:PG:Cholesterol in varying ratios to customize releasing drugs in timed release from 40 to 200 days the ratios selected from the group consisting of 60:10:0:30; 65:5:5:25 and 60:5:5:30. 2. The drug of claim 1 selected from the group consisting of anti-VEGF antibodies, Bevacizumab (Avastin), Ranibizumab (Lucentis), Pegaptanib (Macugen), Aflibercept (Eylea), Atropine, Flurbiprofen, Physostimine, Azopt, Gentamicin, Pilocarpine, Bacitracin, Goniosol, Polymyxin B, Betadine, Gramicidin, Prednisolone, Betaxolol, Humorsol, Proparacaine, Betoptic, Hylartin, Propine, Brinzolamide, Hypertonic NaCl, Puralube, BSS, Indocycanine Green, Rose Bengal, Carbachol, Itraconazole, Sodium Hyaluronate, Cefazolin, Latanoprost, Suprofen, Celluvisc, Mannitol, Terramycin, Chloramphenicol, Methazolamide, Timolol, Ciloxan, Miconazole, Tobramycin, Ciprofloxacin, Miostat, Triamcinolone, Cosopt, Muro 128, Trifluridine, Demecarium, Neomycin, Tropicamide, Dexamethasone, Neptazane, Trusopt, Dipivefrin, Ocuflo, Vidarabine, Dorzolamide, Ofloxacin, Vira-A, Epinephrine, Oxytetracycline, Viroptic, Fluorescein, Phenylephrine and Xalatan, and combinations thereof. 3. The formulation of claim 1 further comprising a coating wherein the surface of the liposomes are modified by PEGylation to improve stability.

Details for Patent 9,962,333

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2033-08-16
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	06/30/2006		2033-08-16
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	08/10/2012		2033-08-16
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	10/13/2016		2033-08-16
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	03/20/2018		2033-08-16
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387	11/18/2011		2033-08-16